Drug Trial Radar · NCT07946367
Dual-targeting of B & T Cell Pathways Evaluation Trial
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
Dec 1, 2026
Primary completion
Aug 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Diabetes Free, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human study of DFI205, an investigational bispecific antibody that binds CD20 and CD40, with the goal of targeting both B- and T-cell function in adults with active systemic autoimmune rheumatic diseases (SARDs) despite standard therapy. In Phase 1, participants with RA, SLE, SSc or IIM will receive a single dose at increasing dose levels to establish safety and initial treatment response. The selected dose will be carried forward into Phase 2a, where participants will receive monthly doses to assess safety and treatment response.
Conditions
- Rheumatoid Arthritis (RA)
- Systemic Lupus Erythematosus (SLE)
- Systemic Sclerosis (SSc)
- Idiopathic Inflammatory Myopathies (IIM)
Interventions
DFI205 bispecific antibodyDrug
A bispecific monoclonal antibody that binds to both CD20 and CD40 receptors on cells.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the initial safety and tolerability of DFI205 in adults with SARDsTime frame: Up to 1 year post-dosing
- To monitor immune reconstitution after completion of dosing with DFI205Time frame: Up to 1 year post-dosing
- To monitor immune response to DFI205Time frame: Up to 1 year post-dosing
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Universitaetsklinikum Erlangen AöR
Erlangen, Germany · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.